Next-Generation Antibody Therapeutics Market Outlook by Therapeutic Area (Oncology, Autoimmune/Inflammatory), Technology (Antibody–Drug Conjugates, Bispecific Antibodies, Fc-Engineered Antibodies, Antibody Fragments and Antibody-Like Proteins, Biosimilar Antibody Products) - Global Industry Revenue Estimation to 2030

Market Overview

The global next-generation antibody therapeutics market size stood at $5,619.7 million in 2021, which is expected to reach $15,308.6 million by 2030, advancing at a CAGR of 11.8% during 2021–2030. This will predominantly be due to the advancements in the monoclonal antibody technology, which displays high safety and efficacy.

The promulgating investments in the healthcare sector are set to expand the market size in the upcoming period as well. This will mainly be due to the high success rate of antibodies in the treatment of various chronic diseases, such as autoimmune diseases and cancer. Apart from mAbs, antibody–drug conjugates (ADCs) are being developed to combat the surge in the incidence of chronic diseases. The increase in government grants further encourages the prominent players to increase their R&D activities, which would yield higher revenue in the industry once the candidates have been approved for marketing.

Furthermore, the advancements in the biopharmaceutical field are leading to a high demand for antibodies for the treatment of infectious diseases, neurological disorders, and cancer. Biopharmaceuticals are extremely useful for the management of various neurodegenerative disorders, as these conditions require the drugs to be administered directly into the brain, which is not possible with traditional medications.

The advancements in glycoengineered antibodies, ADCs, and bispecific antibodies have led to the development of antibody therapeutics with improved characteristics.

Oncology Category Leads Market

The oncology category accounted for the larger revenue share, of approximately 80%, in 2021, and it is expected to show the higher CAGR, of around 13%, in the forecast period. This is because of the rising incidence of breast cancer, colorectal cancer, prostate cancer, brain cancer, and lung cancer, where antibody therapeutics offer benefits throughout the treatment. In addition, the availability of various next-generation antibody therapeutics, such as Kadcyla, ADCETRIS, and Poteligeo, for the treatment of cancer patients has intensified the domain revenue.

Antibody–Drug Conjugates To Witness Fastest Growth

The ADC category accounted for the largest revenue share in 2021, and the same category is set to register the highest CAGR, of around 12%, in the forecast period. The category growth is mainly due to the high demand for antibody-based cancer therapy, coupled with the rising incidence of breast cancer, technological advancements, and a rapid increase in the number of these conjugates under clinical trials.

Additionally, the adoption of the cleavable linker technology is expected to provide significant growth opportunities to the eponymous category, due to its high stability in the bloodstream for a prolonged duration and effective release of cytotoxins from ADCs at the targeted tumor site. In developing countries, such as China, the technology is extensively being used for the treatment of relapsing systemic anaplastic large-cell lymphoma and relapsing Hodgkin's lymphoma.

Several key players, such as Janssen Pharmaceutical Companies, ADC Therapeutics, Seagen Inc., and AstraZeneca plc, are actively involving in collaborations, for enhancing their revenue and customer base. For instance, in February 2022, Mersana Therapeutics Inc. announced its partnership with Janssen Pharmaceutical Companies for the R&D of novel ADCs, to treat numerous cancers.

Furthermore, the increase in pharma funding by both private as well as public organizations, for the production of novel ADCs, is expected to drive the next-generation antibody therapeutics market growth in the forecast period.

Moreover, in recent years, there has been a swift increase in the incidence of multiple myeloma all over the world, which is driving the demand for ADCs. Additionally, the several initiatives taken by federal agencies in support of these therapeutic candidates are expected to boost the revenue for pharma and biopharma firms. For instance, in August 2020, the FDA approved GlaxoSmithKline's first anti-BCMA therapy, BLENREP, for the treatment of refractory multiple myeloma.

Explore more about this report - Request free sample pages

North America Is Leader in Market

North America dominated the market in 2021 with a value of around $2.5 billion, primarily ascribed to the surge in the funds for R&D by government as well as non-government organizations. In addition, the escalation in the prevalence of chronic diseases in the region is driving the sector size. In the region, the U.S., followed by Canada, is expected to dominate the regional market during the forecast period, propelled by the increasing per capita healthcare expenditure.

Furthermore, the presence of prominent key players in the region, surge in the approval of next-generation antibody therapeutics, and existence of well-established research facilities drive the market growth.

APAC is set to register the highest CAGR, of around 13%, in the forecast period, primarily attributed to the rising number of strategic partnerships amongst the prominent players in the region. In addition, the accelerating R&D activities in the field of next-generation antibodies in China, India, and Japan are driving the regional sector development. Furthermore, the increase in the government support for drug R&D and for establishing pharma manufacturing facilities in the region are snowballing the market growth.

Europe held significant market share in 2021, driven by the increasing investments in biotechnology in the region. This has led to the high acceptance of next-generation antibody therapeutics for chronic inflammatory and autoimmune diseases. In addition, the rising number of drug approvals in the region intensifies the sector development. Moreover, in the European market, the oncology category held the largest share in 2021, owing to the extensive product innovations, which have raised their utility for treating a diversity of malignant tumors.

Adoption of ADC Technology Is Key Trend

The ADC technology is gaining traction in the next-generation antibody therapeutics market, as the cytotoxic nature of antibodies is considered to have a potential benefit in chemotherapy. This property is expressed and its efficacy and specificity are regulated by these conjugates. Owing to the high efficiency delivered by ADCs, pharmaceutical and biotechnology companies across the world are increasingly focusing on their development.

Cancer is one of the major application areas of ADC-based next-generation antibody therapeutics. Several pharma companies, including Seagen Inc. and F. Hoffmann-La Roche Ltd., are engaged in the development of next-generation antibody therapeutics that are based on this technology. The surge in the demand for antibodies due to the continuous increase in the chronic disease incidence has led to the rapid approval of ADCs by the FDA.

Top Players in Next-Generation Antibody Therapeutics Market Are:

• F. Hoffmann-La Roche Ltd.
• Kyowa Kirin Co. Ltd.
• Seagen Inc.
• ImmunoGen Inc.
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Pfizer Inc.
• Catalent Inc.
• AstraZeneca plc
• Xencor Inc.

Market Size Breakdown by Segment

The study offers a comprehensive market segmentation analysis along with market estimation for the period 2017-2030.

Based on Therapeutic Area

• Oncology
• Autoimmune/Inflammatory

Based on Technology

• Antibody–Drug Conjugates (ADCs)
• Bispecific Antibodies
• Fc-Engineered Antibodies
• Antibody Fragments and Antibody-Like Proteins
• Biosimilar Antibody Products

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa